The marker "EBNA1 (IgG)" is a crucial indicator for assessing neurological health and potential autoimmune conditions affecting the nervous system. EBNA1 stands for Epstein-Barr Nuclear Antigen 1, and the IgG designation refers to Immunoglobulin G, a type of antibody. This particular marker is significant because it helps detect past infections with the Epstein-Barr virus (EBV), which is known to be associated with a variety of neurological disorders. EBV is a common virus, and while it often causes mild symptoms or goes unnoticed in many people, its connection to neurological conditions can be significant in a subset of individuals. The presence of IgG antibodies against EBNA1 indicates that a person has been infected with EBV at some point in their life, and their immune system has produced antibodies to fight off the virus. In the context of the NeuralZoomer Plus panel, testing for EBNA1 (IgG) antibodies helps healthcare providers understand whether a past EBV infection might be contributing to neurological symptoms or conditions. This information is valuable for developing a comprehensive picture of a patient's neurological health and tailoring treatment approaches to address any identified autoimmune or viral-related issues.

EBV-VCA, IgG is an antibody (protein) that is produced by the body in an immune response to an Epstein-Barr virus antigen.

EBV-VCA, IgM is an antibody (protein) that is produced by the body in an immune response to an Epstein-Barr virus antigen.

EBV stands for Epstein-Barr virus.

Epstein-Barr virus is a virus that typically causes a mild to moderate illness. Blood tests for Epstein-Barr virus detect antibodies to EBV in the blood and help establish a diagnosis of EBV infection.

VCA stands for Viral capsid antigen.

– Anti-VCA IgM appears early in EBV infection and usually disappears within four to six weeks.

– Anti-VCA IgG appears in the acute phase of EBV infection, peaks at two to four weeks after onset, declines slightly then persists for the rest of a person’s life.

EBV CAPSID Ag.ab/IgG is an antibody (protein) that is produced by the body in an immune response to an Epstein-Barr virus antigen.

EBV CAPSID Ag.Ab/IgM is an antibody (protein) that is produced by the body in an immune response to an Epstein-Barr virus antigen.

If the result of the Epstein-Barr Virus Early Antigen IgG (EBV EA IgG) test falls within the reference range, it generally indicates one of the following scenarios:

1. No Active or Recent EBV Infection: A result within the reference range typically suggests that there is no active or recent infection by the Epstein-Barr Virus. EBV EA IgG antibodies are usually present during the acute phase of an EBV infection. Their absence or low levels within the normal range implies that the individual is likely not in the acute phase of EBV infection.

2. Past Infection: Individuals who have had an EBV infection in the past and have since recovered will often have EBV EA IgG levels within the reference range. After the acute phase of the infection, these antibody levels usually decline and may fall back into the reference range.

3. Latency: EBV can remain latent in the body after the initial infection. A reference range result for EBV EA IgG indicates that the virus is not actively replicating or causing active symptoms, consistent with a latent or dormant state of the virus.

4. Possible Immunity: If a person has been exposed to EBV in the past, they may have developed immunity to the virus. In such cases, other types of EBV antibodies (like VCA IgG or EBNA IgG) might be present, while EA IgG remains within the reference range, indicating a past infection and possible immunity.

5. Early or Very Late Stage of Infection: In very early stages of an EBV infection or in cases where a significant amount of time has passed since the infection, EA IgG levels might still be within the reference range. This is because it takes time for these antibodies to develop post-infection, and they tend to decline in later stages.

It's important to interpret these results in the context of other EBV-specific antibody tests (like VCA IgM, VCA IgG, and EBNA IgG) and the clinical presentation of the patient. The EBV antibody profile, including the EA IgG result, provides a more comprehensive understanding of the individual's infection status. A healthcare provider can best interpret what this result means in the context of an individual's symptoms, history, and overall health.

Aid in the diagnosis of acute EBV (infectious mononucleosis) and EBV reactivation in conjunction with other serologic tests. The appearance of IgG antibodies to Early antigen-diffuse [EA(D)] is generally associated with the primary (acute) stage of EBV infection. For most individuals these antibodies are transient and are often undetectable after 6 months.

The EBV Early Antigen Ab, IgG is a valuable biomarker in the diagnosis and management of Epstein-Barr virus infections. By understanding the presence and levels of these antibodies, healthcare providers can better determine the phase of EBV infection and provide appropriate treatment strategies. If you suspect an EBV infection or are experiencing prolonged symptoms, consult your healthcare provider about testing for EBV Early Antigen Ab, IgG.

The Epstein-Barr Virus Nuclear Antigen Antibody (EBV Nuclear Ag Ab) test is a significant component of the Epstein-Barr Virus VCA (Viral Capsid Antigen) Antibody Panel, playing a critical role in diagnosing and understanding the Epstein-Barr Virus (EBV) infection. EBV, a widespread virus, is known for causing infectious mononucleosis and is linked to several other conditions, including certain cancers and autoimmune diseases. The EBV Nuclear Ag Ab test specifically detects antibodies developed against the nuclear antigen of the Epstein-Barr Virus, which are antibodies the immune system produces in response to EBV's nuclear material.

The EBV (Epstein Barr) Nuclear Antigen Antibodies, IgG test looks for a type of antibody which the body typically develops in response to Epstein-Barr Virus.

EBNA antibodies usually appear 2-4 months after infection and persist for the life of the person.  This test is usually performed to establish a past infection with EBV.

The marker EBV PCR Whole Blood LOG signifies the level of Epstein-Barr Virus (EBV) DNA in whole blood, measured using a quantitative PCR (polymerase chain reaction) method. The value is reported both in international units per milliliter (IU/ml) and as a logarithmic value (LOG). This measurement indicates the viral load of EBV present in the blood.

EBV is associated with various diseases, including infectious mononucleosis and certain cancers. Quantitative PCR allows precise measurement of viral DNA levels, aiding in monitoring EBV-related diseases.

The reported value helps clinicians assess the severity of infection or disease progression.

This test is intended to be used for the quantitative detection of Epstein-Barr virus (EBV) DNA and as an aid in the diagnosis and management of EBV infections.

→ This test is only used as an aid in monitoring EBV-related disease.

→ It is not appropriate for the diagnosis of mononucleosis; order serological testing Epstein-Barr Viral Ab Panel instead.

Epstein-Barr Virus (EBV) VCA IgG is a crucial antibody tested in the Epstein-Barr Virus VCA (Viral Capsid Antigen) Antibody Panel, commonly used to diagnose and monitor EBV infections. EBV, a member of the herpesvirus family and one of the most common human viruses, is known for causing infectious mononucleosis and has been linked to various forms of cancer and autoimmune diseases. The EBV VCA IgG test specifically measures the IgG antibodies that the immune system produces in response to the viral capsid antigen of the Epstein-Barr Virus. These antibodies typically develop during the acute or recent phase of an EBV infection and can remain in the system for life, providing long-term immunity.

EBV-VCA, IgG is an antibody (protein) that is produced by the body in an immune response to an Epstein-Barr virus antigen.

The marker ECP on a LabCorp panel refers to Eosinophil Cationic Protein, a protein released by activated eosinophils—white blood cells involved in the body's immune response, particularly in allergic reactions and parasitic infections. ECP plays roles in immune regulation and has cytotoxic and neurotoxic properties.

eGFR stands for estimated glomerular filtration rate. Your eGFR score is a reflection of your blood test for creatinine, a waste product formed in muscular metabolism. It estimates how well your kidneys are working.

Alternative Names: GFR; Estimated GFR; eGFR

What is GFR?

GFR is a blood test that measures how much blood your kidneys filter each minute, which is known as your glomerular filtration rate (GFR). You have two kidneys. Their main job is to filter wastes and extra water out of your blood to make urine. eGFR is a measure of how well your kidneys are working. Measuring serum creatinine along with an estimated glomerular filtration rate (eGFR) is recommended as the first step in GFR evaluation by current clinical practice guidelines. Your eGFR is an estimated number based on a blood test and your age, sex, body type and race. eGFR is considered a mostly reliable test for doctors to know how well your kidneys are working. However, the eGFR may not be accurate if you are younger than 18, pregnant, very overweight or very muscular. In addition, other tests such as  an ultrasound or a kidney biopsy may be ordered to find a cause of your kidney disease.